Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 734 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Degarelix Accord September 14, 2023 Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... December 9, 2020 Load more HOT NEWS Can Artificial Intelligence Help See Cancer in New, and Better, Ways? Palliative and Supportive Care for Children With Cancer: An Expert Perspective 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:...
